
-
Kodiak Sciences Inc. NasdaqGM:KOD Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Location: 1200 Page Mill Road, Palo Alto, CA, 94304, United States | Website: https://kodiak.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
116.7M
Cash
138.9M
Avg Qtr Burn
-26.7M
Short % of Float
10.40%
Insider Ownership
5.52%
Institutional Own.
81.86%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KSI-501 (anti-VEGF & IL-6) Details Eye disease , Wet age-related macular degeneration | Phase 3 Data readout | |
Tarcocimab (KSI-301) (anti-VEGF) Details Non-proliferative diabetic retinopathy | Phase 3 Data readout | |
KSI-101 Details Eye disease | Phase 2b Data readout | |
KSI-501 (anti-VEGF & IL-6) Details Diabetic macular edema, Eye disease | Phase 1 Update | |
Tarcocimab (KSI-301) (anti-VEGF) Details Diabetic macular edema | Failed Discontinued | |
Tarcocimab (KSI-301) Details Retinal vein occlusion | Failed Discontinued | |
Tarcocimab (KSI-301) Details Wet age-related macular degeneration | Failed Discontinued |